Literature DB >> 32767044

Evaluation of the discussion of late effects and screening recommendations in survivors of adolescent and young adult (AYA) lymphoma.

Andrea C Lo1,2, Vanessa Samuel3, Ben Chen3, Kerry J Savage3,4,5, Ciara Freeman3,4,5, Karen Goddard6,3.   

Abstract

PURPOSE: The study objective was to assess the discussion of late effects (LEs) and screening recommendations (SRs) for adolescent and young adults (AYAs) treated for lymphoma.
METHODS: A retrospective study was conducted on AYA lymphoma survivors aged 15-24 years at diagnosis who received radiation therapy (RT) ± chemotherapy between 1984 and 2010 at any of the six British Columbia (BC) Cancer treatment centers across the province. Charts were reviewed to evaluate discussion of LEs and SRs. Susceptibility to specific LEs was determined by reviewing treatment details.
RESULTS: Of 305 patients, 212 (70%) had documented discussion of at least one specific LE, 39 (13%) had non-specific documentation only, and 54 (18%) had no documented discussion of LEs. Accounting only for patients susceptible to each LEs, the most frequently discussed LEs was radiation-induced (RI) neoplasm (42%), and the least frequently discussed LEs was carotid artery stenosis (0.4%). The most common SRs discussed in susceptible patients was for RI breast cancer (43%). Of patients discharged between 1985 and 1999 vs 2000 and 2014, LEs were discussed in 63 vs 93% (P < 0.0005), and SRs were discussed in 30 vs 65%, respectively (P < 0.0005). Older age at discharge, presence of a discharge note, and occurrence of a discharge appointment were associated with increased discussion of SRs.
CONCLUSIONS: Most survivors of AYA lymphoma received some discussion of LEs and SRs, but each relevant LEs and SRs was discussed in only a minority of susceptible patients. IMPLICATIONS FOR CANCER SURVIVORS: Survivors of AYA lymphoma and their primary care professionals may not be appropriately informed of health risks and how to screen for them.

Entities:  

Keywords:  Adolescent and young adult; Documentation; Late effects; Lymphoma; Radiation therapy; Radiotherapy

Year:  2020        PMID: 32767044     DOI: 10.1007/s11764-020-00922-7

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  37 in total

1.  Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Authors:  Michael Schaapveld; Berthe M P Aleman; Anna M van Eggermond; Cécile P M Janus; Augustinus D G Krol; Richard W M van der Maazen; Judith Roesink; John M M Raemaekers; Jan Paul de Boer; Josée M Zijlstra; Gustaaf W van Imhoff; Eefke J Petersen; Philip M P Poortmans; Max Beijert; Marnix L Lybeert; Ina Mulder; Otto Visser; Marieke W J Louwman; Inge M Krul; Pieternella J Lugtenburg; Flora E van Leeuwen
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

2.  Late cardiotoxicity after treatment for Hodgkin lymphoma.

Authors:  Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Marie L De Bruin; Mars B van 't Veer; Margreet H A Baaijens; Jan Paul de Boer; Augustinus A M Hart; Willem J Klokman; Marianne A Kuenen; Gabey M Ouwens; Harry Bartelink; Flora E van Leeuwen
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

3.  Use of recommended posttreatment services for adolescent and young adult survivors of Hodgkin lymphoma.

Authors:  Erin E Hahn; Yi-Lin Wu; Corrine E Munoz-Plaza; Jazmine Garcia Delgadillo; Robert M Cooper; Chun R Chao
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

Review 4.  Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop.

Authors:  Sharyl J Nass; Lynda K Beaupin; Wendy Demark-Wahnefried; Karen Fasciano; Patricia A Ganz; Brandon Hayes-Lattin; Melissa M Hudson; Brenda Nevidjon; Kevin C Oeffinger; Ruth Rechis; Lisa C Richardson; Nita L Seibel; Ashley W Smith
Journal:  Oncologist       Date:  2015-01-07

5.  Childhood, adolescent, and young adult cancer survivors research program of British Columbia: objectives, study design, and cohort characteristics.

Authors:  Mary L McBride; Paul C Rogers; Sam B Sheps; Victor Glickman; Anne-Marie Broemeling; Karen Goddard; Joan Hu; Maria Lorenzi; Stuart Peacock; Sheila Pritchard; Shahrad Rod Rassekh; Linda Siegel; John J Spinelli; Paulos Teckle; Lijing Xie
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

6.  Critical issues in transition and survivorship for adolescents and young adults with cancers.

Authors:  Paul C Nathan; Brandon Hayes-Lattin; Jeffrey J Sisler; Melissa M Hudson
Journal:  Cancer       Date:  2011-05-15       Impact factor: 6.860

7.  Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

Authors:  Frederika A van Nimwegen; Michael Schaapveld; Cécile P M Janus; Augustinus D G Krol; Eefke J Petersen; John M M Raemaekers; Wouter E M Kok; Berthe M P Aleman; Flora E van Leeuwen
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

8.  Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer.

Authors:  Paul Craig Nathan; Christopher Keller Daugherty; Kristen Elizabeth Wroblewski; Mackenzie Louise Kigin; Tom Vernon Stewart; Fay Jarmila Hlubocky; Eva Grunfeld; Marie Elisabeth Del Giudice; Leigh-Anne Evelyn Ward; James Mahlon Galliher; Kevin Charles Oeffinger; Tara Olive Henderson
Journal:  J Cancer Surviv       Date:  2013-03-08       Impact factor: 4.442

Review 9.  Cancer in Adolescents and Young Adults: A Narrative Review of the Current Status and a View of the Future.

Authors:  Ronald D Barr; Andrea Ferrari; Lynn Ries; Jeremy Whelan; W Archie Bleyer
Journal:  JAMA Pediatr       Date:  2016-05-01       Impact factor: 16.193

10.  Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study.

Authors:  Adam P Yan; Yan Chen; Tara O Henderson; Kevin C Oeffinger; Melissa M Hudson; Todd M Gibson; Joseph P Neglia; Wendy M Leisenring; Kirsten K Ness; Jennifer S Ford; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui; Paul C Nathan
Journal:  J Clin Oncol       Date:  2020-03-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.